InvestorsHub Logo
Followers 12
Posts 1261
Boards Moderated 0
Alias Born 04/12/2011

Re: None

Monday, 01/16/2017 2:08:41 PM

Monday, January 16, 2017 2:08:41 PM

Post# of 108192
Aduro Biotech is collaborating with Merck to study the combination of Aduro’s Listeria-based immunotherapy CRS-207 with Merck’s anti-PD-1 Keytruda (pembrolizumab) in gastric cancer patients. The multicenter Phase 1 clinical trial, which will enroll metastatic gastric cancer patients who failed at least two prior therapies, is expected to begin in the first half of 2017.

This from oncology news weekly.
I'm still wondering why Merck chose them rather than us, given what we believe to be superior technology?
Wish the checkpoint inhibitors were more tightly restricted to tumors.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News